Search

Conozca los últimos avances en el tratamiento contra el cáncer pulmonar en MSK.

… Friday, November 15, 2024 El cáncer pulmonar es el segundo cáncer más común y sigue siendo la principal causa de muerte por cáncer en los Estados Unidos. Sin embargo, una variedad de nuevos tratamientos, muchos de ellos desarrollados o probados en el Memorial Sloan Kettering Cancer Center (MSK), están

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.

… Saturday, January 1, 2011 Summary To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. The goal of the new

Thanks to pioneering work done at MSK, a powerful new form of radiation therapy is changing the treatment of advanced cancers.

… Thursday, September 11, 2025 A high-intensity radiation beam that penetrates the body to burn away tumors has been a standard weapon against cancer for more than a century. Over the years, radiation therapy has improved dramatically, but its effectiveness against cancers in multiple places can be limited

Learn about important advances in the treatment of pancreatic cancer.

… Thursday, June 5, 2025 Many people have questions about pancreatic cancer and its prognosis. MSK surgeon-scientist and pancreatic cancer expert Vinod Balachandran, MD, discusses why the disease is so hard to detect, what the latest treatment options are, and how promising research may improve survival

The Cycle for Survival community, along with founding partner, Equinox, achieves a historic fundraising milestone, fueling rare cancer research at Memorial Sloan Kettering.

… Thursday, April 28, 2022 Cycle for Survival, the movement to beat rare cancers, made history by surpassing $300 million in total funds raised through its signature stationary-cycling events. Since 2007, more than 1 million participants worldwide, including patients, caregivers, survivors, as well as

Learn how MSK uses the watch-and-wait approach to rectal cancer, which can preserve people's quality of life by successfully treating rectal cancer without removing the rectum.

… Friday, February 28, 2025 There’s an alternative for treating some patients with  rectal cancer that makes it possible to avoid  surgical removal of the rectum and the related side effects, which can include changes to sexual function and fertility and the possibility of a permanent ostomy bag — a pouch

Descubra cómo MSK utiliza el enfoque de observación y espera para el cáncer de recto, que permite preservar la calidad de vida de los pacientes al tratar con éxito el cáncer de recto sin necesidad de extirpar el recto.

… Friday, February 28, 2025 Existe una alternativa para tratar a algunos pacientes con cáncer de recto que permite evitar la extirpación quirúrgica del recto y los efectos secundarios relacionados, que pueden incluir cambios en la función sexual y la fertilidad y la posibilidad de tener que usar una bolsa

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation, or chemotherapy.

… Sunday, April 27, 2025 An approach pioneered at Memorial Sloan Kettering Cancer Center (MSK) that caused rectal cancer tumors with a specific genetic mutation to disappear in 100% of clinical trial participants has been expanded to treat other types of cancer, including stomach (gastric) , colon , esophageal

Obtenga información sobre un ensayo clínico en el que se utilizó únicamente inmunoterapia para tratar a personas con varios tipos diferentes de cáncer, lo que significa que no tuvieron que someterse a cirugía, radioterapia ni quimioterapia.

… Sunday, April 27, 2025 Un enfoque en el que Memorial Sloan Kettering Cancer Center (MSK) fue pionero y que hizo que los tumores de cáncer de recto con una mutación genética específica desaparecieran en el 100 % de los participantes en el ensayo clínico se ha ampliado para tratar otros tipos de cáncer

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.

… Tuesday, January 29, 2019 Bottom Line: Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD , has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells